Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis

Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-0143. Epub 2017 Dec 1.

Abstract

Aim: This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab.

Materials & methods: Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 months of treatment (n = 90). Significant SNPs for univariate analysis were subjected to multivariate analysis.

Results: Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months.

Conclusion: Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.

Keywords: adalimumab; anti-TNF drugs; infliximab; pharmacogenetics; psoriasis.

Publication types

  • Observational Study

MeSH terms

  • Adalimumab / therapeutic use*
  • Adult
  • Anti-Inflammatory Agents / therapeutic use*
  • Biomarkers / metabolism
  • Dermatologic Agents / therapeutic use*
  • Female
  • Humans
  • Infliximab / therapeutic use*
  • Male
  • Multivariate Analysis
  • Pharmacogenetics / methods
  • Polymorphism, Single Nucleotide / genetics
  • Prospective Studies
  • Psoriasis / drug therapy*
  • Psoriasis / genetics*

Substances

  • Anti-Inflammatory Agents
  • Biomarkers
  • Dermatologic Agents
  • Infliximab
  • Adalimumab